News
Together Women’s Health partners up with menopause care delivery platform

The US women’s health company Together Women’s Health has teamed up with a leading care delivery platform to help women on their menopause journey.
Together Women’s Health has announced a strategic partnership with the digital menopause care delivery platform true. Women’s Health, which offers a personalised, membership-based concierge medicine model, focusing on midlife, menopause, sexual health and weight management.
Every woman will go through menopause, with 78 per cent of women experiencing physical and emotional symptoms that can have a negative impact on their well-being and work.
Despite the severity of these symptoms, only one in five women in the US are referred to a menopause specialist. More than 70 per cent of the women who seek medical attention for menopausal symptoms are left untreated and remain significantly underserved.
true.’s care process aims to make it easier to see how every aspect of a patient’s life fits together to make them well or unwell as they age. The true. programme includes guidance and support in ten specific areas of wellness and delivers care through virtual interactions and tools.
“The true. model will significantly enhance our capabilities at Together Women’s Health, driving improved healthcare outcomes and elevating the patient experience at every stage of a woman’s healthcare journey,” said Anthony Ahee, CEO at Together Women’s Health.
“We are excited about our partnership with true. Women’s Health as it will enhance our virtual care strategy and provide specialised care to women across the country.
“This will complement the services offered by hundreds of affiliated women’s healthcare providers in various locations in the United States.”
Dr Diana Bitner, co-founder and chief medical officer at true. Women’s Health, said: “When we launched true. in 2019, our goal was to leverage technology and clinical expertise to fill a significant unmet need and dramatically improve women’s lives.
“Together Women’s Health is the ideal partner to scale our delivery of menopause and wellness care with our digital health platform. Together, we’re improving the standard of care for women in their post-reproductive years, no matter where they live.
“We are thrilled to join forces and look forward to the years of collaboration and growth ahead.”
To receive the Femtech World newsletter, sign up here.
Menopause
Perimenopause misinformation ‘putting women at risk’
Cancer
Early PET scan could chemo response in aggressive breast cancer – study
News
Femtech World reveals startup of the year shortlist

We are excited unveil the three finalists competing for one of the Femtech World Awards’ most coveted honours: the Startup of the Year Award, sponsored by Future Fertility.
This award celebrates an early-stage company making a bold impact in women’s health through innovation, vision and execution.
The winner will be announced at our virtual ceremony on 19 June, with the decision made by a representative from category sponsor Future Fertility.
Congratulations to the shortlist and thank you to everyone who entered or nominated.
Startup of the Year Shortlist

Hello Inside is the first women’s health AI company to turn daily metabolic signals into outcomes women feel and healthcare systems reimburse.
Women’s health has long been under-researched, and current AI benchmarks fail on women’s health questions roughly sixty percent of the time.
Hello Inside built the architecture to close that gap.
Across four years and 12,000+ validated metabolic profiles, three in four women improve at least one symptom within ninety days.
They lose four kilograms in three months, moving from overweight into the healthy range. In a clinical study with Alisa Vitti’s Flo Living, 91.9 per cent reduced PMS burden within sixty days.


U-Ploid is an early-stage biotechnology company tackling one of the most fundamental challenges in fertility care: the sharp, age-related decline in egg quality that limits outcomes across IVF and egg freezing.
While much of the field focuses on improving assessment and selection, U-Ploid is developing a first-in-class therapeutic approach designed to improve egg quality itself by addressing the biological causes of age-related chromosomal errors.
Supported by strong preclinical evidence and now advancing into human studies, U-Ploid combines scientific rigour, regulatory discipline and long-term vision to help redefine what is possible in fertility care.
News4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Insight4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness4 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Opinion3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Hormonal health4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS














